The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Welcome stories


16 April 2007
16/04/2007 Sinclair Pharma plc to Main Market

16 April 2007

 

The London Stock Exchange is delighted to welcome Sinclair Pharma plc to the Main Market.




Sinclair Pharma is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries.


Sinclair has expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.


The company floated on AIM in December 2003 at 115p and a market capitalisation of £61.8m. As at close of play 11 April 2007 share price was 122.5p and market cap is now £114.8m. As part of its transfer to the Main Market, Sinclair Pharma has also applied to join techMARK mediscience.


The new listing on the Main Market is expected to increase liquidity in the ordinary shares, and enhance the domestic and international profile of the Company. In recent years, Sinclair Pharma has expanded its international presence, and now has significant and expanding activities in continental Europe.

.

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds